Veracyte price target raised to $47 from $37 at Morgan Stanley
Morgan Stanley raised the firm's price target on Veracyte to $47 from $37 and keeps an Underweight rating on the shares. The firm is updating its model ahead of the earnings report.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.